HUNK — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1204208	0.69	1/20
SCHEMBL3543710	0.67	1/20
SCHEMBL4106452	0.67	1/20
SCHEMBL4103261	0.65	1/20
SCHEMBL4103266	0.65	1/20
SCHEMBL4114464	0.65	1/20
SCHEMBL1560694	0.64	1/20
Plogosertib (SCHEMBL1202614)	0.60	1/20
Plogosertib (SCHEMBL1202855)	0.60	1/20
SCHEMBL1203731	0.60	1/20
Plogosertib (SCHEMBL12879990)	0.60	1/20
Plogosertib (SCHEMBL29919216)	0.60	1/20
SCHEMBL1202993	0.58	1/20
SCHEMBL12880331	0.58	1/20
SCHEMBL1675823	0.57	1/20
SCHEMBL1675826	0.57	1/20
SCHEMBL31229765	0.57	1/20
SCHEMBL13551746	0.57	1/20
SCHEMBL12880499	0.57	1/20
SCHEMBL12880468	0.55	1/20

Clinical trials — most relevant to HUNK by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors	PHASE2	RECRUITING
Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC	PHASE2	COMPLETED
Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer	PHASE2	COMPLETED
A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer	PHASE2	COMPLETED
A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
HER-2 Protein Vaccine in Treating Women With Breast Cancer	PHASE1	COMPLETED
Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing	PHASE1	COMPLETED
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b	PHASE1	COMPLETED
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients	nan	RECRUITING
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study	nan	COMPLETED
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib	nan	COMPLETED
Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis	nan	UNKNOWN
Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)	nan	RECRUITING
Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)	nan	COMPLETED
Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer	nan	WITHDRAWN
Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma	nan	COMPLETED
Genetic Study of CYP2D6 Enzyme and Therapeutic Drug Monitoring of Tamoxifen	nan	UNKNOWN
Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly	nan	COMPLETED
Study of Adrenal Gland Tumors	nan	COMPLETED
IRS Proteins and Trastuzumab Resistance	nan	COMPLETED
An Observational Study of Current Practice Pattern on the Treatment of Women With Metastatic Breast Cancer Whose Tumors Overexpress Her2neu	nan	COMPLETED
Integrated Testing Strategy for Simultaneous Detection of ESR-1 and gBRCA Mutations Via Liquid Biopsy in HR+/HER2- Metastatic Breast Cancer (mBC) Patients,	nan	RECRUITING
Radical Fimbriectomy for Young BRCA Mutation Carriers	nan	ACTIVE_NOT_RECRUITING
Thyroid Lobectomy With or Without Levothyroxine Treatment Postoperatively	nan	COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
The Effects of HER2 Receptor Signaling on Human Brown Fat Activity	nan	RECRUITING
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA	nan	RECRUITING
UNFOLD Study Egypt	nan	COMPLETED
Study of Tissue Samples From Women Treated With Paclitaxel for Breast Cancer on Clinical Trial CALGB-9344 or CALGB-9741	nan	COMPLETED
PIK3CA in HER2+ BC and pCR Trial	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a HUNK binder may also engage these)

Protein	Name	Similarity
Q68UT7	—	1.000	Q68UT7 →
O88866	—	0.999	O88866 →
Q3UIZ8	—	0.994	Q3UIZ8 →
Q8C0X8	—	0.993	Q8C0X8 →
Q8VDU5	—	0.993	Q8VDU5 →
NUAK2	NUAK family SNF1-like kinase 2	0.992	landscape →
Q9QYZ6	—	0.992	Q9QYZ6 →
Q5R8Z4	—	0.992	Q5R8Z4 →
Q8BMD7	—	0.992	Q8BMD7 →
Q9LHI7	—	0.992	Q9LHI7 →
NUAK1	NUAK family SNF1-like kinase 1	0.991	landscape →
Q6IVY4	—	0.991	Q6IVY4 →
A5PLL1	—	0.991	A5PLL1 →
Q5R810	—	0.991	Q5R810 →
Q66HE5	—	0.991	Q66HE5 →
CAMKK2	Calcium/calmodulin-dependent protein kinase kinase 2	0.991	landscape →
Q641K5	—	0.991	Q641K5 →
SRPK1	SRSF protein kinase 1	0.991	landscape →
E1BE02	—	0.991	E1BE02 →
E9Q9W7	—	0.990	E9Q9W7 →
NEK4	Serine/threonine-protein kinase Nek4	0.990	landscape →
B1WAS2	—	0.990	B1WAS2 →
Q9H5P4	—	0.990	Q9H5P4 →
Q9JHS1	—	0.990	Q9JHS1 →
Q8N103	—	0.990	Q8N103 →
Q9H329	—	0.990	Q9H329 →
Q5BIW4	—	0.990	Q5BIW4 →
Q80VH0	—	0.990	Q80VH0 →
Q3UJB9	—	0.990	Q3UJB9 →
A4Q9E8	—	0.990	A4Q9E8 →